Mobile

A trial investigating the safety and efficacy of the drug combination Sofosbuvir/Velpatasvir/GS-9857 for 8 weeks against Sofosbuvir/Velpatasvir for 12 weeks for subjects with hepatitis C

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-002996-12

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the efficacy of treatment with sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 fixed dose combination (FDC) for 8 weeks and of treatment with SOF/VEL FDC for 12 weeks as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR12) To evaluate the safety and tolerability of each treatment regimen

Critère d'inclusion

  • Chronic hepatitis C virus infection

Liens